Clinical Trial Update: Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating AZD8931 in combination with paclitaxel versus paclitaxel alone in metastatic gastric/gastroesophageal junction cancer was terminated, w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• AZD8931 (AZD8931)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: AstraZeneca | Conditions: Metastatic, Gastric or Gastro-oesophageal Junction, Cancer | Phase 2 | Status: TERMINATED | Results posted: 2014-09-12